Francesco Schettini, Physician-Scientist at the Breast Unit of the Hospital Clinic of Barcelona and IDIBAPS, shared a post on LinkedIn:
“RIBOLARIS interim analysis results show that neoadjuvant Ribociclib+ET in clinically high-risk patients can ensure that in more than 50% cases a post-surgical Prosigna ROR low is obtained.
The next step will be to understand if this translates into adequate DMFS rates at 5 years!
To note, the mean ROR score was basically below the threshold for Low risk according to standard Prosigna cut-offs in all patients! It will be interesting to see if this has a positive overall impact on long-term outcomes.
Great study from Aleix Prat.”
More posts featuring Francesco Schettini on OncoDaily.
